Seroprevalence of hepatitis B and C viruses in patients with chronic kidney disease in the predialysis stage at a university hospital in Turkey

Intervirology

Volumn 50, Issue 2, 2007, Pages 133-137

  Sit, Dede ^a,b   Kadiroglu, Ali Kemal ^a   Kayabasi, Hasan ^a   Yilmaz, M Emin ^a   Goral, Vedat ^a  

^a DICLE UNIVERSITY   (Turkey)

^b DICLE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Anti hepatitis C virus; Chronic kidney disease; Hepatitis B surface antigen

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; HEPATITIS C ANTIBODY;

ADOLESCENT; ADULT; AGED; ALPORT SYNDROME; AMYLOIDOSIS; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; CHRONIC GLOMERULONEPHRITIS; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DIALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODIALYSIS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; NEPHROSCLEROSIS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RENOVASCULAR HYPERTENSION; SEROPREVALENCE; TURKEY (REPUBLIC); UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS C; HEPATITIS C ANTIBODIES; HOSPITALS, UNIVERSITY; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; SEROEPIDEMIOLOGIC STUDIES; TURKEY;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 33846963163     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000098239     Document Type: Article

References (25)

1. NKF-K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification and stratification. Am J Kidney Dis 2002;39:S1-S266.
2. Vanholder R, Van Biesen W: Incidence of infectious morbidity and mortality in dialysis patients. Blood Purif 2002;20:477-480.
3. Boyacioglu S: The problem of chronic hepatitis B in patients with chronic kidney failure; in Tabak F, Balik I, Tekeli E (eds): Viral Hepatitis 2005 (in Turkish). Istanbul, Society of Struggle against Viral Hepatitis Publications, 2005, pp 105-118.
4. Mahoney FJ: Update on diagnosis and management of hepatitis B virus infection. Clin Microbiol Rev 1999;12:351-366.
5. Alessandro A, Coppo R: Effect on the immune response; in Davison AM, Cameron JS, Grünfeld JP, Ponticelli C, Ritz E, Winearls CG, Ypersele C (eds): Clinical Nephrology, ed 3. London, Oxford University Press, 2005, vol 3, pp 1868-1874.
6. Turgut H, Turhanoǧlu M, Aydin K, Arikan E, Degertekin H, Ariturk S: Anti-HCV positivity in different groups (in Turkish). J Gastroenterol 1992;3:640-642.
7. Salako BL, Ayodele OE, Kadiri S, Arije A: Prevalence of hepatitis B and C viruses in pre-dialysis patients with chronic renal failure. Afr J Med Med Sci 2002;31:311-314.
8. Chandra M, Khaja MN, Hussain MM, et al: Prevalence of hepatitis B and hepatitis C viral infections in Indian patients with chronic renal failure. Intervirology 2004;47:374-376.
9. Alter MJ: Epidemiology and prevention of hepatitis B. Semin Liver Dis 2003;23:39-46.
10. Registry of the Nephrology, Dialysis and Transplantation in Turkey (in Turkish). Registry, 2004.
11. Akpolat T, Arik N, Gunaydin M, et al: Prevalence of Anti-HCV among hemodialysis patients in Turkey: a multicenter study. Nephrol Dial Transplant 1995;10:479-480.
12. Dundar IH, Inal AS: Viral hepatitis from past to today; in Tabak F, Balik I, Tekeli E (eds): Viral Hepatitis 2005 (in Turkish). Istanbul, Society of Struggle Against Viral Hepatitis Publications, 2005, pp 10-20.
13. Centers for Disease Control and Prevention: Consultant Meeting to Update Recommendations for the Prevention and Control of Bloodborne and Other Infections among Chronic Hemodialysis Patients. Atlanta, Georgia 1999. MMWR 2001;50:1-43.
14. Centers for Disease Control and Prevention: Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998;47:19-21.
15. Zoulim F: Hepatitis C virus infection in special groups. J Hepatol 1999;31(suppl 1):130-135.
16. Pol S, Vallet-Pichard A, Fontaine H, Lebray P: HCV infection and hemodialysis. Semin Nephrol 2002;22:331-339.
17. Kausz A, Pahari D: The value of vaccination in chronic kidney disease. Semin Dial 2004;17:9-11.
18. Lemon SM, Thomas DL: Vaccines to prevent viral hepatitis. N Engl J Med 1997;336:196-204.
19. Miller ER, Alter MJ, Tokars JI: Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Am J Kidney Dis 1999;33:356-360.
20. Lai CL, Ratziu V, Yuen MF, Poynard T: Viral hepatitis B. Lancet 2003;362:2089-2094.
21. Mesjasz J, Wiecek A, Gonciarz Z, Mazur W, Kokot F: Does long-term erythropoietin therapy influence the prevalence of serum markers of hepatitis B and C in haemodialysed uraemic patients? Pol Merkuriusz Lek 2004;16:362-367.
22. Sirmatel F, Karatas M, Turker M, Bozkurt AI: Hepatitis B and C carriage in sex workers according to years (in Turkish). J Viral Hepatitis 1997;1:70-72.
23. Dursun M, Ertem M, Yilmaz S, et al: Prevalence of hepatitis B infection in the southeastern region of Turkey: comparison of risk factors for HBV infection in rural and urban areas. Jpn J Infect Dis 2005;58:15-19.
24. Fabrizi F, Lunghi G, Poordad FF, Martin P: Management of hepatitis B after renal transplantation: an update. J Nephrol 2002;15:113-122.
25. Boyacioglu S: Hepatitis B virus infection in hemodialysis and renal transplantation. Diagnosis and Treatment of Chronic Hepatitis B and Delta Viruses 'National Consensus Meeting' (in Turkish). 3rd National Hepatology Congress Book, 1999, pp 50-58.